First brazilian consensus of advanced prostate cancer: recommendations for clinical practice
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOC UROL
Autores
SASSE, Andre Deeke
WIERMANN, Evanius Garcia
HERCHENHORN, Daniel
SCHUTZ, Fabio A.
MALUF, Fernando Cotait
MORBECK, Igor Alexandre Protzner
CERCI, Juliano J.
SMALETZ, Oren
Citação
INTERNATIONAL BRAZ J UROL, v.43, n.3, p.407-415, 2017
Resumo
Introduction: Prostate cancer still represents a major cause of morbidity, and still about 20% of men with the disease are diagnosed or will progress to the advanced stage without the possibility of curative treatment. Despite the recent advances in scientific and technological knowledge and the availability of new therapies, there is still considerable heterogeneity in the therapeutic approaches for metastatic prostate cancer. Objectives: This article presents a summary of the I Brazilian Consensus on Advanced Prostate Cancer, conducted by the Brazilian Society of Urology and Brazilian Society of Clinical Oncology. Materials and Methods: Experts were selected by the medical societies involved. Forty issues regarding controversial issues in advanced disease were previously elaborated. The panel met for consensus, with a threshold established for 2/3 of the participants. Results and Conclusions: The treatment of advanced prostate cancer is complex, due to the existence of a large number of therapies, with different response profiles and toxicities. The panel addressed recommendations on preferred choice of therapies, indicators that would justify their change, and indicated some strategies for better sequencing of treatment in order to maximize the potential for disease control with the available therapeutic arsenal. The lack of consensus on some topics clearly indicates the absence of strong evidence for some decisions.
Palavras-chave
Prostatic Neoplasms, Practice Guideline [Publication Type], Diagnosis
Referências
- Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
- Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
- Carneiro A, 2015, WORLD J UROL, V33, P1281, DOI 10.1007/s00345-014-1439-6
- Dalesio O, 2000, LANCET, V355, P1491
- de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
- Finlay OG, 2005, LANCET ONCOL, V6, P392
- Fizazi K, 2012, LANCET ONCOL, V13, pE464
- Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0
- Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6
- Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257
- Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0
- James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
- MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405
- Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
- Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7
- Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
- Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
- Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
- [Anonymous], 2016, ESTIMATIVAS 2016 INC